Harpula was formed to foster the growth of next generation technology and services for clinical trials. Our goal is to build a company that excels in today’s clinical trial landscape of personalized medicine, multiple trial modalities, and increased patient centricity. Harpula builds on the founders’ years of experience in clinical trial execution and technology. We recognize the opportunity to build a more coordinated technology solution through acquisition and organic growth. We seek to invest in companies and assets in the technology-enabled pharmaceutical solutions industry to improve the clinical trial experience for patients, sites, and sponsors. Technology solutions have had a tremendously positive impact on the quality and efficiency of clinical trials. As the number and type of solutions have propagated, the burden on sponsors, sites, and patients has increased. There is opportunity to consolidate platforms to address critical pain points around the patient and site experience and ultimately deliver drugs to patients faster.